A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.
Wildfire Exposure Confers Longer Length of Stay Following NSCLC Surgery
Future work may need to assess whether extended hospital stays improve surgical care outcomes during disasters, according to one of the study authors.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
AI Model May Predict Immunotherapy Responses in Advanced NSCLC
Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Novel ADC Elicits Meaningful Activity in Pretreated HER2-Mutant NSCLC
Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.
Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC
Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.